LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report)'s share price rose 6.3% on Wednesday . The company traded as high as $29.77 and last traded at $29.86. Approximately 314,805 shares were traded during trading, an increase of 66% from the average daily volume of 189,582 shares. The stock had previously closed at $28.08.
Analysts Set New Price Targets
LENZ has been the subject of a number of analyst reports. TD Cowen initiated coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They set a "buy" rating and a $60.00 target price for the company. Piper Sandler began coverage on LENZ Therapeutics in a report on Monday, April 14th. They set an "overweight" rating and a $51.00 price objective for the company. Citigroup increased their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, HC Wainwright reiterated a "buy" rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $46.60.
Read Our Latest Research Report on LENZ
LENZ Therapeutics Stock Performance
The firm has a fifty day moving average price of $26.52 and a 200 day moving average price of $26.90. The stock has a market cap of $844.38 million, a PE ratio of -16.95 and a beta of 0.42.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02. On average, equities research analysts forecast that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.
Hedge Funds Weigh In On LENZ Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LENZ. Mirae Asset Global Investments Co. Ltd. purchased a new position in LENZ Therapeutics in the 4th quarter worth $29,000. KLP Kapitalforvaltning AS purchased a new position in LENZ Therapeutics in the 4th quarter worth $46,000. Tower Research Capital LLC TRC raised its stake in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after acquiring an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC purchased a new position in LENZ Therapeutics in the 4th quarter worth $67,000. Finally, Banque Transatlantique SA purchased a new position in LENZ Therapeutics in the 1st quarter worth $119,000. Hedge funds and other institutional investors own 54.32% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
See Also
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
